Overview

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Status:
Not yet recruiting

Trial end date:
2024-08-12

Target enrollment:

Participant gender:

Summary

Primary Objective: Part A - To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score - To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B - To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives - To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients - To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).

Phase:

Phase 4

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborator:

Sanofi